ロード中...
Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation
Background: The recently developed antiandrogen, Enzalutamide (Enz), has reformed the standard of care for castration resistant prostate cancer (CRPC) patients. However, Enz-resistance inevitably emerges despite success of Enz in prolonging CRPC patients’ survival. Here we found that Enz-resistant p...
保存先:
| 出版年: | Cancers (Basel) |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7226306/ https://ncbi.nlm.nih.gov/pubmed/32235588 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040831 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|